ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded by Wall Street Zen to Strong-Buy Rating

Key Points

• Wall Street Zen upgraded ANI Pharmaceuticals from “buy” to “strong-buy,” while other firms have also turned more positive on the stock. Overall, the consensus remains “Moderate Buy” with an average target price of $107.33.
• ANI Pharmaceuticals delivered a strong quarterly beat, posting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. Revenue rose 20.5% year over year, indicating solid growth.
• The company raised its FY 2026 EPS guidance to $9.19-$9.69, above analysts’ expectations. That suggests management sees continued profitability strength ahead even as revenue guidance stays roughly in line with estimates.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a note issued to investors on Saturday.

Several other brokerages also recently commented on ANIP. Guggenheim lifted their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. Zacks Research upgraded ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $107.33.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $81.86 on Friday. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. The business's 50 day moving average is $76.82 and its two-hundred day moving average is $81.01. The company has a market cap of $1.83 billion, a P/E ratio of 24.36 and a beta of 0.46. ANI Pharmaceuticals has a 12 month low of $56.71 and a 12 month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.97% and a net margin of 8.87%.The company's revenue for the quarter was up 20.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts expect that ANI Pharmaceuticals will post 7.64 EPS for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 5,323 shares of the business's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $78.02, for a total value of $415,300.46. Following the transaction, the insider owned 84,840 shares of the company's stock, valued at approximately $6,619,216.80. The trade was a 5.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Ori Gutwerg sold 2,060 shares of the business's stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $76.50, for a total value of $157,590.00. Following the completion of the transaction, the senior vice president directly owned 84,782 shares in the company, valued at approximately $6,485,823. This represents a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 27,860 shares of company stock valued at $2,111,581. Insiders own 8.10% of the company's stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Divisadero Street Capital Management LP bought a new stake in shares of ANI Pharmaceuticals during the third quarter worth $21,454,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of ANI Pharmaceuticals during the third quarter worth $1,597,000. Apis Capital Advisors LLC raised its position in shares of ANI Pharmaceuticals by 28.1% during the third quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company's stock worth $15,022,000 after acquiring an additional 36,000 shares during the last quarter. Decker Retirement Planning Inc. raised its position in shares of ANI Pharmaceuticals by 76,862.5% during the third quarter. Decker Retirement Planning Inc. now owns 36,942 shares of the specialty pharmaceutical company's stock worth $3,384,000 after acquiring an additional 36,894 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of ANI Pharmaceuticals by 791.1% during the third quarter. SG Americas Securities LLC now owns 22,847 shares of the specialty pharmaceutical company's stock worth $2,093,000 after acquiring an additional 20,283 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Key Headlines Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat Wall Street expectations on both earnings and revenue, reporting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. The company also said quarterly revenue rose 20.5% year over year, signaling solid underlying growth. Article Title
• Positive Sentiment: The company raised its FY 2026 EPS guidance to $9.19-$9.69, above the consensus estimate of $8.79, which suggests management sees stronger profitability ahead. Article Title
• Neutral Sentiment: Investors are also parsing the earnings call transcript and presentation for details on the company’s growth drivers and updated strategy, but the main stock catalyst today is the beat-and-raise quarter. Article Title
• Neutral Sentiment: ANI also issued revenue guidance around $1.1 billion for FY 2026, roughly in line with expectations, so the revenue outlook appears stable rather than a fresh upside surprise. Article Title

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.